INNOVATIVE EYEWEAR INC (LUCY)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
$0.82-2.69%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
QuarterlyIQ Insights · LUCY
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
These factors include, among others: adjustments to preliminary net sales arising from completion of the Company’s quarter-end close and the review of its interim financial statements; the timing and…
Stated in a supplied disclosure. Management reported: “These factors include, among others: adjustments to preliminary net sales arising from completion of the Company’s quarter-end close and the review of its interim financial statements; the timing and volume of orders, reorders, shipments and sell-through at the Company’s retail and distribution partners; the timing and market acceptance of new products, including Lucyd Aero™; the Company’s ability to obtain additional financing and to continue as a going concern; and the Company’s ability to maintain compliance with The Nasdaq Stock Market’s continued listing requirements.” “The Company expects to use the net proceeds from the transaction for working capital and general corporate purposes.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Not enough signal yet.
Over the trailing year it converted 0.90x of net income into operating cash flow.
Not enough signal yet.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
At the same time, we opened three new wholesale and international channels during the quarter: a major U.S. big-box retailer, FYihealth Group in Canada, and Directed Electronics in Australia and New…
Stated in a supplied disclosure. Management reported: “The retailer plans to offer the products in more than 150 of its stores nationwide, with in-store sales expected to begin in October 2026.” “The orders are expected to ship in October 2026 and are not included in third quarter net sales.”
That approach clears the way for the planned fourth quarter launch of Lucyd Aero™, our lightest and most advanced smartglasses to date, as we head into what has historically been our strongest quarte…
Stated in a supplied disclosure. Management reported: “These factors include, among others: adjustments to preliminary net sales arising from completion of the Company’s quarter-end close and the review of its interim financial statements; the timing and volume of orders, reorders, shipments and sell-through at the Company’s retail and distribution partners; the timing and market acceptance of new products, including Lucyd Aero™; the Company’s ability to obtain additional financing and to continue as a going concern; and the Company’s ability to maintain compliance with The Nasdaq Stock Market’s continued listing requirements.”
Improve product economics and reduce the company’s reported net losses.
Use proceeds from warrant exercises for working capital and general corporate purposes.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
9 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.